Clarity Pharmaceuticals
在场
Clarity Pharmaceuticals 是一家在股票代码 CU6 (AU) 下上市的公司。
高管
查看带有其 18 名主要高管的组织结构图
Clarity Pharmaceuticals 搜索最多的简介
- Michelle Parker, Chief Executive Officer
- Chris Roberts, Non-Executive Director
- Colin Biggin, Excecutive Director
高管在Clarity Pharmaceuticals变化
- Colin Biggin 曾任 Director, Managing Director and Chief Executive Officer, 现任 Excecutive Director (新闻发布的2024十月14号).
- Michelle Parker 曾任 Director and Executive Vice President, Global Clinical Operations, 现升职为 Chief Executive Officer (新闻发布的2024十月14号).
- Robert Thomas, Lead Independent Director, 正在办理退休 (新闻发布的2024八月26号).
创建提醒
跟踪 Clarity Pharmaceuticals 的高管变动
药店
Clarity Pharmaceuticals 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Clarity Pharmaceuticals 的最新新闻稿
- Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity’s COBRA study selected as a Top-Rated Oral Presentation at prestigious industry Annual Meeting - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity promotes Michelle Parker to CEO - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Copper-67 SAR-bisPSMA updates - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity launches $121 million fully underwritten equity raising - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity successfully completes Placement and Institutional Entitlement Offer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- SECuRE update: First participant treated in the last cohort of dose escalation - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity’s theranostic prostate cancer trial advances to multi-dose phase - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- View more press releases Close
通过电子邮件
